Eton Pharmaceuticals IncNASDAQ:ETON
- LAST PRICE10.7500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots9.0000/ 2
- Ask / Lots11.0000/ 1
- Open / Previous Close--- / 10.7500
- Day Range---
- 52 Week Range
- Volume1
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ETON |
|---|---|---|
| 09:32 ET | 7617 | 10.24 |
| 09:37 ET | 485 | 10.37 |
| 09:39 ET | 2929 | 10.21 |
| 09:44 ET | 150 | 10.2832 |
| 09:51 ET | 420 | 10.26 |
| 09:57 ET | 200 | 10.295 |
| 10:02 ET | 1100 | 10.3025 |
| 10:06 ET | 100 | 10.295 |
| 10:09 ET | 200 | 10.36 |
| 10:11 ET | 100 | 10.3276 |
| 10:31 ET | 100 | 10.3808 |
| 10:36 ET | 206 | 10.392 |
| 10:38 ET | 302 | 10.42 |
| 10:42 ET | 700 | 10.46 |
| 10:49 ET | 841 | 10.41 |
| 10:51 ET | 100 | 10.415 |
| 10:54 ET | 100 | 10.41 |
| 11:02 ET | 200 | 10.385 |
| 11:03 ET | 10000 | 10.3609 |
| 11:05 ET | 100 | 10.42 |
| 11:07 ET | 1831 | 10.45 |
| 11:20 ET | 1000 | 10.4799 |
| 11:21 ET | 100 | 10.5 |
| 11:25 ET | 4245 | 10.4 |
| 11:27 ET | 300 | 10.405 |
| 11:30 ET | 100 | 10.405 |
| 11:32 ET | 844 | 10.4 |
| 11:34 ET | 1021 | 10.435 |
| 11:43 ET | 100 | 10.41 |
| 11:45 ET | 100 | 10.39 |
| 11:48 ET | 100 | 10.4 |
| 11:50 ET | 100 | 10.4 |
| 11:52 ET | 250 | 10.4 |
| 11:57 ET | 100 | 10.4 |
| 11:59 ET | 4700 | 10.37 |
| 12:01 ET | 264 | 10.37 |
| 12:06 ET | 100 | 10.41 |
| 12:12 ET | 100 | 10.3807 |
| 12:15 ET | 100 | 10.35 |
| 12:17 ET | 2100 | 10.36 |
| 12:21 ET | 100 | 10.39 |
| 12:32 ET | 200 | 10.33 |
| 12:33 ET | 299 | 10.33 |
| 12:35 ET | 100 | 10.355 |
| 12:37 ET | 1499 | 10.32 |
| 12:51 ET | 1100 | 10.36 |
| 01:08 ET | 107 | 10.38 |
| 01:09 ET | 1351 | 10.4 |
| 01:22 ET | 100 | 10.43 |
| 01:26 ET | 13472 | 10.435 |
| 01:29 ET | 300 | 10.44 |
| 01:31 ET | 100 | 10.46 |
| 01:33 ET | 674 | 10.4962 |
| 01:40 ET | 5212 | 10.49 |
| 01:42 ET | 2438 | 10.5 |
| 01:44 ET | 5774 | 10.49 |
| 01:45 ET | 4380 | 10.5 |
| 01:47 ET | 300 | 10.5 |
| 01:49 ET | 499 | 10.5 |
| 01:51 ET | 800 | 10.5 |
| 01:54 ET | 9999 | 10.49 |
| 01:58 ET | 700 | 10.48 |
| 02:00 ET | 377 | 10.45 |
| 02:07 ET | 235 | 10.48 |
| 02:12 ET | 2233 | 10.41 |
| 02:25 ET | 100 | 10.435 |
| 02:30 ET | 6192 | 10.5 |
| 02:32 ET | 19242 | 10.5 |
| 02:34 ET | 2176 | 10.495 |
| 02:36 ET | 11073 | 10.6 |
| 02:38 ET | 1300 | 10.635 |
| 02:43 ET | 200 | 10.635 |
| 02:45 ET | 1617 | 10.67 |
| 02:50 ET | 600 | 10.61 |
| 02:52 ET | 400 | 10.6 |
| 02:57 ET | 3502 | 10.55 |
| 03:08 ET | 17376 | 10.679 |
| 03:10 ET | 100 | 10.67 |
| 03:14 ET | 100 | 10.67 |
| 03:15 ET | 100 | 10.67 |
| 03:19 ET | 100 | 10.67 |
| 03:24 ET | 730 | 10.68 |
| 03:26 ET | 800 | 10.665 |
| 03:28 ET | 800 | 10.68 |
| 03:30 ET | 400 | 10.66 |
| 03:32 ET | 804 | 10.66 |
| 03:33 ET | 17468 | 10.69 |
| 03:35 ET | 1793 | 10.68 |
| 03:37 ET | 256 | 10.6955 |
| 03:39 ET | 518 | 10.685 |
| 03:42 ET | 822 | 10.67 |
| 03:44 ET | 534 | 10.62 |
| 03:46 ET | 200 | 10.63 |
| 03:48 ET | 2972 | 10.65 |
| 03:50 ET | 11976 | 10.76 |
| 03:51 ET | 3269 | 10.75 |
| 03:53 ET | 21851 | 10.76 |
| 03:55 ET | 1000 | 10.75 |
| 03:57 ET | 3022 | 10.75 |
| 04:00 ET | 17141 | 10.75 |
Nov 13, 2024
DJ Eton Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 8:58AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:58AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Eton Pharmaceuticals 3Q EPS 2c >ETON, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution), from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024, from 4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:30PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eton Pharmaceuticals Inc | 277.7M | -50.4x | --- |
Zevra Therapeutics Inc | 487.3M | -4.7x | --- |
Cipla Ltd | 14.0B | 0.0x | --- |
Scilex Holding Co | 105.8M | -0.4x | --- |
Aoxing Pharmaceutical Company Inc | 4.9M | -0.8x | --- |
Universe Pharmaceuticals Inc | 2.8M | 0.0x | --- |
Company Information
Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.
Contact Information
- Headquarters
- 21925 W Field Pkwy Ste 235DEER PARK, IL, United States 60010-7278
- Phone
- 847-787-7361
- Fax
- ---
Executives
- Independent Chairman of the Board
- Norbert Riedel
- President, Chief Executive Officer, Director
- Sean Brynjelsen
- Chief Financial Officer, Treasurer, Company Secretary
- James Gruber
- Chief Business Officer
- David Krempa
- Independent Director
- Jennifer Adams
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $277.7M |
|---|---|
Revenue (TTM) | $34.7M |
Shares Outstanding | 25.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-0.21 |
Book Value | $0.60 |
P/E Ratio | -50.4x |
Price/Sales (TTM) | 8.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
